Head

Profile_image

Prof. Dr. Thomas F. Meyer

Phone:+49 30 28460-402Fax:+49 30 28460-401
Email:meyer@...

Contact

Veronika Meier

Phone:+49 30 28460-404

Dr. Sigrid Gödert

Phone:+49 30 28460-453

Dr. Rike Zietlow

Phone:+49-30-28460-461

Publications

Links and further information

Molecular Biology

Molecular Biology

During his Ph.D. at the Max Planck Institute for Medical Research in Heidelberg, Thomas F. Meyer started his career by establishing an in vitro replication system of bacteriophage fd. In 1980 he became interested in mobile elements and began pioneering investigations of the molecular basis of pilin antigenic variation in Neisseria with Prof. M. So at the Cold Spring Harbor Laboratory and the Public Research Institute, New York, as a postdoctoral fellow.

Back in Heidelberg as a staff scientist at ZMBH (Centre for Molecular Biology of Heidelberg University) in 1982, he discovered the first example of variable gene expression based on the variation of short repeats (slipped strand mispairing). After moving to MPI for Biology, Tübingen, he discovered neisserial IgA protease as the first example of the large family of bacterial autotransporter proteins and explored its secretory pathway.

In the late 80's his focus shifted gradually towards the pathogen-host cell interface, where he discovered central adhesins and host cell receptors crucial for the neisserial infection. As appointed Director of the Department of Infection Biology in Tübingen (1990) and Founding Director of the new Max Planck Institute for Infection Biology in Berlin (1994), he continued to explore crucial aspects of pathogen-host cell interactions using Neisseria, Chlamydia and Helicobacter as key model systems.

After relocating to MPI's new purpose built facilities in 2001, and with the discovery of short interfering RNAs (siRNA) applicable to gene knockdown in human cells, he placed an emphasis on the exploration of human gene function during infection. Besides other projects, he coordinated the EU FP6 RIGHT project on the application of RNAi for human therapy (2005 to 2009). He is now Director of the Molecular Biology Department and his lab runs Europe's unique BSL3 screening facility.

Prof. Meyer holds professorships at the Charité University Medicine and the Humboldt University, Berlin, and is a member of EMBO and the German Academy of Sciences Leopoldina. His current research interests focus on the global understanding of infection processes, the manifestation of heritable epigenetic marks upon infection, and the sequels of long-term chronic infection, such as cancer.

Departmental Overview

Here in the Molecular Biology Department we recognize that elucidation of the mechanisms of infectious disease will only result from the understanding of the specific interactions between pathogen and host cells. Our current research focuses on the understanding of molecular and cellular foundations of these complex, subtle and dynamic liaisons.

Taking a multidisciplinary approach that encompasses cell biology, functional genomics, proteomics and epigenetics, we are using extracellular (Helicobacter, Neisseria), obligate intracellular (Chlamydia), facultative (Legionella, Salmonella) and viral (Influenza) pathogen models to advance our understanding of the pathogen-host tet-a-tet. Emphasis is placed on the interface between host and pathogen to understand bacterial virulence mechanisms, receptor-mediated interactions with host target cells, pathogen induced host cell signaling events, and the strategies and underlying mechanisms facilitating pathogen survival and replication within its host.

Furthermore, these investigations are helping us to understand the role of infection and inflammation in cancerogenesis and cell degeneration and aiding the development of vaccines and identification of novel drug targets. To achieve our scientific goals, cutting edge investigative techniques are being employed enabling pathogen genetics, high resolution live- cell microscopy, as well as functional gene analysis using RNA interference, alongside other global approaches. We stand at the precipice of elucidation and understanding that may provide the possibility of tangible solutions to current and future worldwide infectious diseases and their associated symptoms.

 
loading content